KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Income (2016 - 2025)

Historic Operating Income for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$132.1 million.

  • CRISPR Therapeutics AG's Operating Income fell 1991.19% to -$132.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$574.4 million, marking a year-over-year decrease of 7280.55%. This contributed to the annual value of -$466.6 million for FY2024, which is 10965.68% down from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Operating Income is -$132.1 million, which was down 1991.19% from -$229.3 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's Operating Income's 5-year high stood at $762.6 million during Q2 2021, with a 5-year trough of -$229.3 million in Q2 2025.
  • Its 5-year average for Operating Income is -$78.9 million, with a median of -$132.1 million in 2025.
  • In the last 5 years, CRISPR Therapeutics AG's Operating Income soared by 104513.25% in 2021 and then plummeted by 19282.15% in 2024.
  • CRISPR Therapeutics AG's Operating Income (Quarter) stood at -$145.7 million in 2021, then grew by 9.72% to -$131.5 million in 2022, then soared by 152.9% to $69.6 million in 2023, then tumbled by 192.82% to -$64.6 million in 2024, then crashed by 104.46% to -$132.1 million in 2025.
  • Its Operating Income was -$132.1 million in Q3 2025, compared to -$229.3 million in Q2 2025 and -$148.4 million in Q1 2025.